A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)
-
Hájek, R. (University Hospital Ostrava)
;
Masszi, T. (St László Hospital (Hongria)) ;
Petrucci, M. T. (Sapienza Università di Roma) ;
Palumbo, A. (Università di Torino) ;
Rosiñol, L. (Hospital Clínic i Provincial de Barcelona) ;
Nagler, Arnon. (Chaim Sheba Medical Center (Israel)) ;
Yong, K. L. (University College London Cancer Institute) ;
Oriol, Albert (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Minarik, J. (University Hospital Olomouc (Olomouc, República Txeca)) ;
Pour, L. (University Hospital Ostrava) ;
Dimopoulos, Meletios (The National and Kapodistrian University of Athens) ;
Maisnar, V. (Charles University. Faculty of Medicine in Hradec Králové) ;
Rossi, Davide (Amedeo Avogadro University of Eastern Piedmont) ;
Kasparu, H. (Ordensklinikum Linz Elisabethinen) ;
Van Droogenbroeck, J. (AZ Sint-Jan, Brugge, Belgium) ;
Yehuda, D. B. (Hadassah Medical Center, Jerusalem, Israel) ;
Hardan, I. (Meir Medical Center, Kfar-Saba, Israel) ;
Jenner, M. (University Hospital Southampton NHS Foundation Trust (Regne Unit)) ;
Calbecka, M. (Nicolaus Copernicus Hospital, Toruń Poland) ;
Dávid, M. (University of Pécs, Hungary) ;
de la Rubia, Javier (Hospital Universitari i Politècnic La Fe (València)) ;
Drach, J. (Medical University of Vienna) ;
Gasztonyi, Z. (Petz Aladár Megyei Oktató Kórház, Vasvári Pál, Hungary) ;
Górnik, S. (Zamojski Szpital Niepubliczny, Zamosc, Poland) ;
Leleu, Xavier (Hopital Huriez, CHRU, Lille, France) ;
Munder, M. (University Medicine Mainz, Germany) ;
Offidani, M. (Clinica di Ematologia Azienda Ospedaliero-Universitaria, Ospedali Riuniti di Ancona, Italy) ;
Zojer, N. (Center for Oncology, Hematology with Outpatient Department and Palliative Care, Wilhelminenspital, Vienna, Austria) ;
Rajangam, K. (Onyx Pharmaceuticals, Inc.) ;
Chang, Y. L. (Onyx Pharmaceuticals, Inc.) ;
San-Miguel, J. F. (Clínica Universidad de Navarra. Centro de Investigación Médica Aplicada) ;
Ludwig, H. (Wilhelminen Cancer Research Institute (Viena, Àustria))